AU703139B2 - Methods and compositions for regulation of CD28 expression - Google Patents

Methods and compositions for regulation of CD28 expression

Info

Publication number
AU703139B2
AU703139B2 AU52958/96A AU5295896A AU703139B2 AU 703139 B2 AU703139 B2 AU 703139B2 AU 52958/96 A AU52958/96 A AU 52958/96A AU 5295896 A AU5295896 A AU 5295896A AU 703139 B2 AU703139 B2 AU 703139B2
Authority
AU
Australia
Prior art keywords
oligomer
seq
cells
oligomers
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU52958/96A
Other languages
English (en)
Other versions
AU5295896A (en
Inventor
Robert C Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Americas Inc
Original Assignee
ICN Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/529,878 external-priority patent/US5932556A/en
Application filed by ICN Pharmaceuticals Inc filed Critical ICN Pharmaceuticals Inc
Priority claimed from PCT/US1996/001507 external-priority patent/WO1996024380A1/en
Publication of AU5295896A publication Critical patent/AU5295896A/en
Application granted granted Critical
Publication of AU703139B2 publication Critical patent/AU703139B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU52958/96A 1995-02-09 1996-02-05 Methods and compositions for regulation of CD28 expression Ceased AU703139B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38704195A 1995-02-09 1995-02-09
US08/387041 1995-02-09
US08/529,878 US5932556A (en) 1995-09-17 1995-09-17 Methods and compositions for regulation of CD28 expression
US08/529878 1995-09-17
PCT/US1996/001507 WO1996024380A1 (en) 1995-02-09 1996-02-05 Methods and compositions for regulation of cd28 expression

Publications (2)

Publication Number Publication Date
AU5295896A AU5295896A (en) 1996-08-27
AU703139B2 true AU703139B2 (en) 1999-03-18

Family

ID=27011718

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52958/96A Ceased AU703139B2 (en) 1995-02-09 1996-02-05 Methods and compositions for regulation of CD28 expression

Country Status (7)

Country Link
JP (1) JP2002515013A (cs)
KR (1) KR100258826B1 (cs)
CN (1) CN1181021A (cs)
AU (1) AU703139B2 (cs)
CA (1) CA2211621A1 (cs)
CZ (1) CZ250097A3 (cs)
SK (1) SK108697A3 (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530057A (ja) * 2004-03-31 2007-11-01 ライオンズ アイ インスティチュート リミテッド Ｖｅｇｆ転写物の安定性を調節するための治療的分子
KR101802540B1 (ko) * 2009-09-25 2017-11-28 큐알엔에이, 인크. Ｆｌｇ의 발현 및 활성을 조절함으로써 필라그린(ｆｌｇ)에 관련된 질환의 치료

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) * 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
WO1992016571A1 (en) * 1991-03-25 1992-10-01 The Regents Of The University Of California Composite materials of interpenetrating inorganic and organic polymer networks
WO1994028128A1 (en) * 1993-05-26 1994-12-08 Imperial College Of Science, Technology And Medicine Test and model for polycystic ovary syndrome and male pattern baldness

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) * 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
WO1992016571A1 (en) * 1991-03-25 1992-10-01 The Regents Of The University Of California Composite materials of interpenetrating inorganic and organic polymer networks
WO1994028128A1 (en) * 1993-05-26 1994-12-08 Imperial College Of Science, Technology And Medicine Test and model for polycystic ovary syndrome and male pattern baldness

Also Published As

Publication number Publication date
SK108697A3 (en) 1998-04-08
CA2211621A1 (en) 1996-08-15
JP2002515013A (ja) 2002-05-21
CN1181021A (zh) 1998-05-06
CZ250097A3 (cs) 1998-01-14
AU5295896A (en) 1996-08-27
MX9705963A (es) 1998-08-30
KR100258826B1 (ko) 2000-07-01
KR19980702101A (ko) 1998-07-15

Similar Documents

Publication Publication Date Title
US5932556A (en) Methods and compositions for regulation of CD28 expression
US6994959B1 (en) G-rich oligo aptamers and methods of modulating an immune response
Karras et al. Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-α chain
EP2111449B1 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
US20110262406A1 (en) Compositions and methods for targeted inactivation of hiv cell surface receptors
EP2099911A2 (en) Compositions and methods for targeted inactivation of hiv cell surface receptors
Bahal et al. Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5
EP0810882A1 (en) Methods and compositions for regulation of cd28 expression
WO1996024380A9 (en) Methods and compositions for regulation of cd28 expression
FR2703053A1 (fr) Oligonucléotides agrafes et semi-agrafes, procédé de préparation et applications .
WO2003048362A2 (en) Suppression of polymeric alleles
EP1008649A2 (en) Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-b2(TGF-b2)
CA2273203A1 (en) Antisense inhibition of human adhesion molecules
Opalinska et al. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules
AU703139B2 (en) Methods and compositions for regulation of CD28 expression
WO1999027086A1 (en) Chimeric antisense oligonucleotides against tnf-alpha and their uses
WO1996040157A1 (en) USE OF ANTISENSE OLIGONUCLEOTIDES TO IL-6 RECEPTOR mRNA TO INHIBIT CELLULAR PROLIFERATION
Cohen Gene-mimetic substances: drugs designed to intervene in gene expression
US6238917B1 (en) Asymmetric hammerhead ribozymes
MXPA97005963A (en) Methods and compositions for the regulation of the expression of c
MXPA99005880A (en) G-rich oligo aptamers and methods of modulating an immune response

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired